139 related articles for article (PubMed ID: 26367752)
1. Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study.
Draelos ZD
Cutis; 2015 Aug; 96(2):135-41. PubMed ID: 26367752
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of the biphasic release of 0.1% halcinonide cream.
Draelos ZD
J Drugs Dermatol; 2015 Jan; 14(1):89-90. PubMed ID: 25607913
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eszematous dermatoses.
Sudilovsky A; Clewe TH
J Clin Pharmacol; 1975; 15(11-12):779-84. PubMed ID: 1104668
[TBL] [Abstract][Full Text] [Related]
4. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
Uliasz A; Zeichner J; Soung J; Wong V; Lebwohl M
Cutis; 2008 Jun; 81(6):517-9. PubMed ID: 18666395
[TBL] [Abstract][Full Text] [Related]
5. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.
Schwarb FP; Imanidis G; Smith EW; Haigh JM; Surber C
Pharm Res; 1999 Jun; 16(6):909-15. PubMed ID: 10397613
[TBL] [Abstract][Full Text] [Related]
6. Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects.
Takeshi M; Ebihara T; Maekawa K; Yamamoto K; Higo N
Int J Pharm; 2014 Apr; 465(1-2):197-201. PubMed ID: 24530385
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
Lee CS; Koo J
J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
[TBL] [Abstract][Full Text] [Related]
8. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
[TBL] [Abstract][Full Text] [Related]
9. [Thermographic study of the percutaneous absorption of corticosteroids].
Ippolito F; Di Carlo A; Frascione P
G Ital Dermatol Venereol; 1989; 124(1-2):9-12. PubMed ID: 2767722
[TBL] [Abstract][Full Text] [Related]
10. A qualitative estimate of the influence of halcinonide concentration and urea on the reservoir formation in the stratum corneum.
Clarys P; Gabard B; Barel AO
Skin Pharmacol Appl Skin Physiol; 1999; 12(1-2):85-9. PubMed ID: 10325587
[TBL] [Abstract][Full Text] [Related]
11. The tape stripping procedure--evaluation of some critical parameters.
Lademann J; Jacobi U; Surber C; Weigmann HJ; Fluhr JW
Eur J Pharm Biopharm; 2009 Jun; 72(2):317-23. PubMed ID: 18775778
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations.
Au WL; Skinner M; Kanfer I
J Pharm Pharm Sci; 2010; 13(1):11-20. PubMed ID: 20456826
[TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of the cutaneous bioavailability of topically applied maxacalcitol.
Ikeda Y; Hirata K; Kano S; Yanagihara H; Takahara J; Kondo K; Umemura K
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):305-10. PubMed ID: 16082417
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous pharmacokinetics of topically applied maxacalcitol ointment and lotion.
Umemura K; Ikeda Y; Kondo K; Hirata K; Amagishi H; Ishihama Y; Tokura Y
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):289-94. PubMed ID: 18541125
[TBL] [Abstract][Full Text] [Related]
15. Fluocinonide vs halcinonide in atopic dermatitis. A paired comparison of two potent topical corticosteroids.
Silverman A
Cutis; 1979 Mar; 23(3):375-8. PubMed ID: 369775
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of topical clotrimazole formulations: an improved tape stripping method.
Parfitt NR; Skinner MF; Bon C; Kanfer I
J Pharm Pharm Sci; 2011; 14(3):347-57. PubMed ID: 21906479
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
Wiedersberg S; Naik A; Leopold CS; Guy RH
Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
[TBL] [Abstract][Full Text] [Related]
18. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.
Woods MT; Brown PA; Baig-Lewis SF; Simpson EL
J Drugs Dermatol; 2011 Feb; 10(2):171-6. PubMed ID: 21283922
[TBL] [Abstract][Full Text] [Related]
19. The effect of ceramide-containing skin care products on eczema resolution duration.
Draelos ZD
Cutis; 2008 Jan; 81(1):87-91. PubMed ID: 18306855
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the local distribution of topically applied substances inside the stratum corneum determined by tape-stripping to differences in bioavailability.
Weigmann HJ; Lademann J; Schanzer S; Lindemann U; von Pelchrzim R; Schaefer H; Sterry W; Shah V
Skin Pharmacol Appl Skin Physiol; 2001; 14 Suppl 1():98-102. PubMed ID: 11509914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
